Below are featured speakers for the 2019 Constellation Forum.
Adam M. Koppel rejoined Bain Capital in 2016 as Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he worked as a leader within the healthcare sector until 2014. From 2014 to 2016, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. He sits on the Board of Directors of Aptinyx (NASD: APTX), Cerevel Therapeutics, Dicerna Pharmaceuticals (NASD: DRNA), Foghorn Therapeutics, Solid Biosciences (NASD: SLDB) and ViaCyte.
Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey and Co in New Jersey where he served a variety of healthcare companies.
Dr. Koppel sits on the Newton-Wellesley Hospital Board of Trustees, the Boston Museum of Science Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society for Neuroscience Investment Committee. He previously sat on the Board of Temple Beth Elohim in Wellesley MA, from 2014-2017.
Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science.
Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.
Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM’s Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.
Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for “World News Now” and “World News This Morning.”
She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.
Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.
Bruce D. Broussard, President and CEO, joined Humana in 2011. Under his leadership, Humana has created an integrated care delivery model centered on improving health outcomes, driving lower costs, enhancing quality, and providing a simple and personalized member experience. With its holistic approach, Humana is dedicated to improving the health of the communities it serves by making it easy for people to achieve their best health.
Bruce brings to Humana a wide range of executive leadership experience in publicly traded and private organizations within a variety of healthcare sectors, including oncology, pharmaceuticals, assisted living/senior housing, home care, physician practice management, surgical centers and dental networks.
Prior to joining Humana, Bruce was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Bruce served in a number of senior executive roles, including Chief Financial Officer, President, Chief Executive Officer and Chairman of the Board.
Bruce plays a leadership role in key business advocacy organizations such as The Business Council and the American Heart Association CEO Roundtable. He is also a member of the Board of Directors of KeyCorp and the World Economic Forum Health Governors Board.
Christine Guo is a healthcare investor at Wells Fargo Strategic Capital (“WFSC”), the venture capital and private equity arm for Wells Fargo. Wells Fargo Strategic Capital’s healthcare division invests across all sub-sectors of healthcare, including healthcare services, healthcare technology, medical devices, and life sciences.
Christine started her career in financial services at Goldman Sachs and Co’s Healthcare Investment Banking Group and Private Equity Group. She then transitioned to healthcare investing at New Enterprise Associates (NEA), where she focused on healthcare services and digital health investing. Christine then gained operating experience by joining her former digital health portfolio company, Collective Health.
Christine has a MBA from Harvard Business School and a BS and BA from University of Pennsylvania.
Dan Wattendorf, director of Innovative Technology Solutions, leads efforts to identify and create biotechnology platforms that result in new options for global health and oversees the foundation’s strategy to develop and implement new biomarkers, diagnostic tests, and diagnostic services for the developing world.
Prior to joining the foundation in 2016, Dan was program manager at the Defense Advanced Research Projects Agency (DARPA), where he initiated and lead programs in diagnostics, mammalian cell synthetic biology, RNA vaccines, rapid discovery of monoclonal antibodies, immunoprophylaxis by gene transfer, and engineered red blood cells.
Previously, he served as director, Air Force Medical Genetics Center, director of the cancer genetics center at the Walter Reed National Military Medical Center, and was a clinician in the Cancer Genetics Branch, National Cancer Institute, NIH.
Dan holds a B.S. in microbiology from Cornell University and an M.D. with distinction from George Washington University. He completed a residency in family medicine at the National Capital Consortium; a residency in clinical genetics at the National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH); a fellowship in clinical cytogenetics at Georgetown University; and a fellowship in health policy from the Office of the Director, NHGRI, NIH.
He has been a member of the Secretary of Veterans Affairs Genomic Medicine Program Advisory Committee and the Institute of Medicine’s Roundtable on Translating Genomic-Based Research for Health.
Dean Kamen is an inventor, an entrepreneur, and a tireless advocate for science and technology. His roles as inventor and advocate are intertwined—his own passion for technology and its practical uses has driven his personal determination to spread the word about technology’s virtues and by so doing to change the culture of the United States.
As an inventor, he holds more than 440 U.S. and foreign patents, many of them for innovative medical devices that have expanded the frontiers of health care worldwide. While still a college undergraduate, he invented the first wearable infusion pump, which rapidly gained acceptance from such diverse medical specialties as oncology, neonatology, and endocrinology. In 1976, he founded his first medical device company, AutoSyringe, Inc., to manufacture and market the pumps. Then, working with leading diabetes researchers, Dean pioneered the design and adoption of the first portable insulin pump. It was quickly demonstrated that using a pump could much more effectively control patients’ blood glucose levels. . At age 30, he sold AutoSyringe to Baxter Healthcare Corporation.
Following the sale of Auto Syringe, Inc., he founded DEKA Research & Development Corporation to develop internally generated inventions as well as to provide research and development for major corporate clients. Kamen led DEKA’s development of the HomeChoiceTM peritoneal dialysis system for Baxter International Inc. The HomeChoiceTM system allows patients to be dialyzed in the privacy and comfort of their home and quickly became the worldwide market leader. Kamen also led the development of technology to improve slide preparation for the CYTYC (now Hologic Inc.) ThinPrep® Pap Test. Kamen-led DEKA teams have also developed critical components of the UVARTM XTSTM System, an extracorporeal photophereisis device marketed by Therakos, a unit of Johnson & Johnson, for treatment of T-Cell lymphoma. An advanced prosthetic arm in development for DARPA should advance the quality of life for returning injured soldiers. Other notable developments include the HydroflexTM surgical irrigation pump for C.R. Bard, the CrownTM stent, an improvement to the original Palmaz-Schatz stent, for Johnson & Johnson, the iBOTTM mobility device, and the Segway® Human Transporter.
Kamen has received many awards for his efforts. Notably, Kamen was awarded the National Medal of Technology in 2000. Presented by President Clinton, this award was in recognition for inventions that have advanced medical care worldwide, and for innovative and imaginative leadership in awakening America to the excitement of science and technology. Kamen was elected a member of the National Academy of Engineering in 1997. He was awarded the Lemelson-MIT Prize in 2002, and was inducted into the National Inventors Hall of Fame in May 2005. He is a Fellow of the American Institute for Medical & Biological Engineering, as well as many other national and international engineering organizations.
In 2010, Dean hosted the Planet Green television series Dean of Invention. In addition to DEKA, one of Dean’s proudest accomplishments is founding FIRST® (For Inspiration and Recognition of Science and Technology), an organization dedicated to motivating the next generation to understand, use and enjoy science and technology. Founded in 1989, this year FIRST® will serve more than 1,000,000 young people, ages 6 to 18, in more than 86 countries around the globe. Last year, high-school-aged participants were eligible to apply for more than $50 million in scholarships from over 200 leading colleges, universities, and corporations.
Emily Kagan Trenchard is the Vice President of Digital & Innovations Strategy for Northwell Health. Adept at serving as the point of translation between doctors, developers and designers, Emily leads key areas of the business including digital patient experience strategy, use research and analytics, digital product development, and user experience design. She also serves as an advisor to Northwell’s ventures division and the IT Innovation Center, helping identify and develop new technologies.
For over a decade Emily has lead teams in designing and implementing the large-scale applications necessary to connect patients to care, and to keep businesses competitive in a time of radical change. She began her career at the Cardiovascular Research Foundation, developing content and digital engagement tools for women’s heart health. Emily then joined Lenox Hill Hospital as their head of Web Systems, where she spearheaded the development of many consumer health platforms, including the first-ever implementation of the ZocDoc scheduling platform for a hospital. Once Lenox Hill Hospital joined the Northwell family, Emily was tapped to be the system’s Director of Web Technology. In this role she helped start the user experience practice, lead a replatforming of the enterprise content management system, championed the use of open source software, built up the in-house application development team, and lead the move to agile processes.
Emily received her undergraduate education in bio-behavioral science from UC Berkeley, and holds a master’s degree in science writing and communication from MIT. Her executive training was at the Yale School of Management. Emily is a nationally recognized poet, essayist and speaker exploring the ways we can remix the human in healthcare.
Emmanuel Fombu, MD, MBA, is an Ivy League educated physician, author, speaker and healthcare executive turned Silicon Valley entrepreneur. He is a medical futurist, an advocate for value-based healthcare and the 2017 winner of the prestigious New York City Health Business Leaders Boldest Digital Health Influencer Award.
As a medical futurist, Dr. Fombu champions the potential for the internet of things, AI and machine learning to revolutionize the healthcare industry. He’s passionate about m-health, personalized medicine, genomics, nanotechnology, big data, artificial intelligence, machine learning, the internet of things and digital medicine. He serves as an external advisory board member on the Massachusetts Institute of Technology’s MIT.nano project.
Dr. Fombu trained at Emory-Crawford Long Hospital and holds an MBA from Cornell University’s Johnson School of Business and a certification on artificial intelligence from MIT’s Computer Science and Artificial Intelligence Lab. He’s taught allied health students, founded a health and education focused non-profit organization and advocates for patients with rare and chronic diseases. Dr Fombu works extensively with venture capitalists and start-ups in digital health and biotech.
In addition to The Future of Healthcare: Humans and Machines Partnering for Better Outcomes, Dr. Fombu has published multiple scientific papers in world renowned, peer reviewed scientific journals. He lives in New York City.
Esther Dyson (@edyson on twitter) is executive founder of Wellville (@WaytoWellville), a ten-year, five-community project dedicated to showing the value of investing in health (as opposed spending on care). Wellville advises the five US-based Wellville communities on accelerating their own health initiatives, in Clatsop County, OR; Lake County, CA; Muskegon County, MI; North Hartford, CT; and Spartanburg, SC. Dyson is the W2W lead for Muskegon, and is actively involved in policy and fundraising for the project. Wellville’s overall mission is to encourage society to think longer-term and more broadly – from self to community – by illustrating the social and financial benefits of collective investment in human capital.
Wellville favors implementation over innovation: applying approaches known to work, at scale in small communities where scale is relatively easy to achieve in terms of both resources and political buy-in. Each community sets its own priorities and goals around issues such as early childhood experiences, obesity/diabetes, mental health, dental health, smoking, addiction and overall human capacity and health disparities; W2W assists in finding partners and funders, and in managing accountability. Over its 10-year life (through 2024), Wellville will measure its progress both year by year and at the end, using both specific program-based metrics and overall goals . Its mission is not just to help five small (<200,000 people) communities get healthy, but to scale by inspiring other communities and funders to copy its example and to think long-term, for the benefit of all. Its motto is “Don’t rent your health. Invest in it!” Aside from that full-time role, Dyson spends her extra time investing in and nurturing start-ups, with a recent focus on health care (somewhat constrained to avoid conflicts with Wellville). On the health side, she is an investor in 23andMe, 4D Healthware, Basil Health, Big Health, Boundless.ai, Care.Coach, CareMESH, Clover Health, Devoted Health, Doppel, Eligible, Enso Relief, Epistemic.ai, Ezra.com, Hawthorne Effect, HealthCelerate, HealthTap, i2Dx, MealShare, Medesk, MedicaSafe, mEquilibrium, Nanowear, NeuroGeneCES, Nuna, Omada Health, PatientsKnowBest, Prognos.ai, Proofpilot, Resilient, Sapiens DS, Solera (also an advisor), StartupHealth, Supportiv, Syllable.ai, Tega Pharmaceutical, Tocagen, Trusty.care, Turbine.ai, Valkee, Virgo, X-VAX and Zipongo.
France A. Córdova is an astrophysicist and the 14th director of the National Science Foundation (NSF), the only government agency charged with advancing all fields of scientific discovery, technological innovation, and science, technology, engineering and mathematics (STEM) education. NSF is a $7.5 billion independent federal agency; its programs and initiatives keep the United States at the forefront of science and engineering, empower future generations of scientists and engineers, and foster U.S. prosperity and global leadership.
Córdova is president emerita of Purdue University, and chancellor emerita of the University of California, Riverside, where she was a distinguished professor of physics and astronomy. Córdova was the vice chancellor for research and professor of physics at the University of California, Santa Barbara.
Previously, Córdova served as NASA’s chief scientist. Prior to joining NASA, she was on the faculty of the Pennsylvania State University where she headed the department of astronomy and astrophysics. Córdova was also deputy group leader in the Earth and space sciences division at Los Alamos National Laboratory. She received her Bachelor of Arts degree from Stanford University and her doctorate in physics from the California Institute of Technology.
More recently, Córdova served as chair of the Board of Regents of the Smithsonian Institution and on the board of trustees of Mayo Clinic. She also served as a member of the National Science Board (NSB), where she chaired the Committee on Strategy and Budget. As NSF director, she is an ex officio member of the NSB.
Córdova’s scientific contributions have been in the areas of observational and experimental astrophysics, multi-spectral research on x-ray and gamma ray sources and space-borne instrumentation. She has published more than 150 scientific papers. She has been awarded several honorary doctorates, including ones from Purdue and Duke Universities. She is a recipient of NASA’s highest honor, the Distinguished Service Medal, and was recognized as a Kilby Laureate. The Kilby International Awards recognize extraordinary individuals who have made “significant contributions to society through science, technology, innovation, invention and education.” Córdova was elected to the American Academy of Arts and Sciences and is a National Associate of the National Academies. She is also a fellow of the American Association for the Advancement of Science (AAAS) and the Association for Women in Science (AWIS).
Córdova is married to Christian J. Foster, a science educator, and they have two adult children.
Geoff Martha is Executive Vice President and President of Medtronic’s Restorative Therapies Group (RTG) – one of four Medtronic business groups – with over $8B in annual revenue and approximately 14,000 employees worldwide. He also serves as a member of the company’s Executive Committee.
Geoff has global responsibility for RTG’s four divisions, which include Brain Therapies, Pain Therapies, Specialty Therapies and Spine. He provides overall strategic direction and operational management, as well as leads the integration of the group’s activities within the overall strategy of Medtronic. Previously, Geoff was Senior Vice President of Strategy and Business Development for Medtronic and had responsibility for leading the development of Medtronic’s global strategic plan, business development and acquisition-integration.
As head of Strategy and Business Development, Geoff led the acquisition of Covidien, a $10 billion global manufacturer of surgical products and supplies. The acquisition of Covidien was the largest medical technology acquisition in the history of the industry. In July 2014, he was named Chief Integration Officer to lead the integration of Covidien into Medtronic.
Geoff serves as the Executive Sponsor of the African-Descent Network – an internal national resource group that focuses on recruitment, engagement, retention and development for Medtronic employees of African descent. An ardent supporter of Medtronic-sponsored philanthropic initiatives, Geoff also is a member of the Medtronic Foundation Board of Directors and serves as Medtronic’s Executive Sponsor to FIRST Robotics.
Prior to joining Medtronic, Geoff served as Managing Director of Business Development at GE Healthcare, where he was responsible for global business development, including acquisitions, divestitures, joint ventures and equity investments. In his 19-year career with GE, which included significant time with GE Capital, Geoff held several executive roles in business leadership, corporate development, strategic marketing, and sales management.
Passionate about socio-economic issues, Geoff serves on the boards of two Minneapolis-based nonprofit organizations: Children’s HeartLink and Northside Achievement Zone (NAZ). Children’s HeartLink provides access to care for children around the world with congenital heart defects. NAZ is a community collaborative that works to end generational poverty and build a culture of achievement in North Minneapolis so low-income children of color graduate college and are career-ready.
Geoff received a bachelor’s degree in Finance as a member of the Scholar’s Program from Pennsylvania State University. He graduated in 1992 with highest honors. Geoff was captain of the Penn State men’s hockey team and was later inducted into its Hockey Hall of Fame in 1998. The University awarded him the 2016 Penn State Hockey Distinguished Alumni Award.
Dr. Geoffrey Ling is a professor of neurology at Johns Hopkins University and the Uniformed Services University of the Health Sciences, attending neuro critical care physician at Johns Hopkins Hospital, acting Vice-Chair for Research in the Department of Clinical Neurosciences at Inova Fairfax Hospital, and Chief Executive Officer of Sun-Q, a biotechnology consulting firm.
Dr. Ling was the Founding Director of the Biological Technologies Office at DARPA and served as the Assistant Director for Medical Innovation in President Obama’s White House Office of Science, Technology and Policy.
Dr. Ling is a retired U.S. Army colonel having served 21 years on active duty. He was deployed to Afghanistan in 2003 and Iraq in 2005 and had four in-theater missions between 2009-2011 for the Joint Chiefs of Staff to assess TBI care in the combat theater. The 10th Combat Support Hospital named him their first “Physician of the Month.” He consulted with Congresswoman Gabby Gifford’s trauma team following her tragic attack.
Dr. Ling received a BA in Biology and History from Washington University in St. Louis, his medical degree from Georgetown University, and a PhD in neuropharmacology from Cornell University. He is board certified in both neurology and neuro critical care.
Dr. Ling has published 200+ peer-reviewed journal articles and book chapters. He was a contributing author or editor of the Guidelines for the Field Management of Combat Related Head Trauma, the VA-DoD Clinical Practice Guidelines for Mild TBI and Concussion, and the chapter on TBI and spinal cord injury in Cecil’s Textbook of Medicine.
Jonathan Bush is the former Chief Executive Officer of athenahealth, Inc. He co-founded the company in 1997 and took it public in 2007 in the most successful initial public offering that year. Today, athenahealth remains one of the healthcare information technology industry’s fastest growing companies.
Bush’s views on healthcare and the idea for athenahealth were born from failures with the earliest iteration of its business model. Bush co-founded and operated a birthing clinic with the idea of franchising a network of clinics that viewed pregnancy holistically. Bush would soon realize that his birthing clinic vision was challenged by his business’s own inability to track outstanding claims to insurers and get paid in a reasonable time-frame. This challenge would shape the formation of athenahealth as it is known today. As a result of the challenges with the clinics, Bush and his partners set about designing a solution to address the costly administrative inefficiencies that plagued their business. In doing so, they came to realize their circumstance was more typical than unique and that the solution they designed had great application and utility for the broader health delivery system. Given his vision for an information infrastructure that makes healthcare work as it should, Bush is focused on creating a true, win-win marketplace that enables a broad and efficient exchange of health information.
In addition, Bush has announced a forthcoming book: “Where Does It Hurt? An Entrepreneur’s Guide to Fixing Health Care.” The book, written together with Steve Baker, author of The Numerati, will be published May 15th.
“Where Does It Hurt” is a provocative, irreverent, sometimes harrowing and, of course, always humorous journey through the dark underbelly of the American healthcare system – why it’s broken, what the fix will involve, and where innovation is already taking hold.
John is Managing Director and a Senior Partner leading Landmark Ventures’ Technology Investment Banking practice. He focuses on providing M&A, private placement and strategic advisory services to growth stage private and public companies across the technology, hardware/semiconductor, digital media, software and Cleantech markets. John leverages extensive relationships across the corporate, PE and VC communities, with a significant cross border focus spanning US, Canada, Europe, Asia and Israel. In his 17 year career, John has successfully closed more than 50 transactions with transaction value exceeding 6 Billion.
Prior to joining Landmark, John was a Senior VP with Jefferies & Co, Inc., a leading global, full-service investment bank targeting middle-market and growth oriented companies. At Jefferies, he focused on M&A and Capital Markets transactions within the technology sectors, including lead coverage responsibility in the hardware, semiconductor/components and communications segments. John joined Jefferies as a VP from Broadview International, a leading technology M&A advisor, which was acquired by Jefferies in December 2003. Prior to Broadview, John was a Senior Associate with Robertson Stephens, focused on technology M&A, private placements and public equity transactions. John started his career with PwC Securities, providing M&A and private placement services to companies across the technology, industrial and consumer markets.
John graduated from Brown University, with a BA in Business Economics.
Justin C. Sanchez is a Battelle Technical Fellow. As a noted expert in biotechnology, he creates strategic vision to guide Battelle’s life sciences research business. Serving on the leadership team, Dr. Sanchez leads the organization’s technical investment strategies and initiates and drives collaboration across Battelle, as well as with government, industry, and academia partners.
Prior to joining Battelle, Dr. Sanchez was the Director of the Biological Technologies Office (BTO) at DARPA. He advanced the mission of BTO through strategy development focused on vital breakthrough technologies and capabilities for national security, particularly in the areas of neurotechnology, gene editing/synthetic biology, and infectious disease. Major accomplishments include developing foundational human neurotechnology for the United States BRAIN Initiative, delivering the world’s most advanced prosthetic arm to military Veterans, accelerating gene editing techniques for national security/human health, and forming partnerships to deliver countermeasures in the African Ebola crisis. He was responsible for starting 31 new DARPA programs and investing more than $1.65 billion at national labs, industry, and academic institutions.
Prior to joining DARPA, he was an associate professor of Biomedical Engineering and Neuroscience at the University of Miami. He directed the Neuroprosthetics Research Group where he oversaw development of neural-interface medical treatments. He has published more than 100 peer-reviewed papers, holds seven patents and authored two books on the design of neurotechnology.
Dr. Sanchez holds a Doctor of Philosophy and Master of Engineering degrees in Biomedical Engineering, and a Bachelor of Science degree in Engineering Science, all from the University of Florida.
Kathleen Gondek, PhD, is currently the Global Head of Outcomes Research and Epidemiology at Takeda.
Kathleen spent the last four years at Shire as Global Head of Outcomes Research and Epidemiology. Prior to joining Shire she was Vice President, US Medical Science Liaisons and Medical Affairs Operations at Bayer HealthCare pharmaceuticals. Prior to this role Kathleen held a number of positions, of increasing responsibility, within the Health Economics and Outcomes Research (HEOR) function at Bayer that span a 15-year career with the organization. These include Director HEOR US, Head of Global HEOR for Life Cycle Management, Anti-infectives, Men’s Health and Oncology and Vice President, Global Health Economics and Outcomes Research, Specialty Medicine. Prior to joining Bayer, Kathleen worked at Boehringer Ingelheim Pharmaceuticals. Kathleen is a coauthor on 45 peer reviewed publications and over 100 presentations.
Kathleen holds a Bachelor’s Degree in Pharmacy from the State University of New York at Buffalo and a PhD in Pharmacy Practice and Administrative Science from the University of Maryland at Baltimore. While at Bayer, Kathleen was a lecturer at Yale University in the School of Public Health.
Kevin J. Tracey is President and CEO of The Feinstein Institutes for Medical Research; Professor of Neurosurgery and Molecular Medicine at the Zucker School of Medicine at Hofstra-Northwell; and Executive Vice President, Research, at Northwell Health, in New York. A leader in the fields of inflammation research and bioelectronic medicine, his contributions to science include discovery and molecular mapping of neural circuits that control immune responses; identifying HMGB1 as a therapeutic target at the intersection of sterile and infective inflammation; and identifying the therapeutic anti-inflammatory activity of monoclonal anti-TNF antibodies. Professor Tracey received his B.S. (Chemistry, summa cum laude, Phi Beta Kappa) from Boston College in 1979, and his M.D. from Boston University in 1983. He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical, Center, and was a guest investigator at the Rockefeller University, before moving in 1992 to The Feinstein Institutes in New York.
An inventor with more than 60 United States patents, and author of more than 360 scientific publications, he is also cofounder of the Global Sepsis Alliance, a non-profit organization supporting the efforts of >1 million caregivers in more than 70 countries. His honors and awards include a Doctorate honoris causa from the Karolinska Institute, Stockholm, Sweden and lectureships from Harvard, Yale, Rockefeller University, the NIH, and elsewhere. He has been elected or inducted into the American Society of Clinical Investigation (2001), the American Association of Physicians (2009), the Long Island Technology Hall of Fame (2012), Alpha Omega Alpha (2014), and is a Fellow in the American Association for the Advancement of Science.
Lance Becker, MD, joined Northwell Health in 2015 as chair of the Department of Emergency Medicine at North Shore University Hospital and Long Island Jewish Medical Center, professor and chair of emergency medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and an investigator at the Feinstein Institute for Medical Research.
A national and international leader in academic emergency medicine, critical care and resuscitation science, Dr. Becker has research interests that are translational and extend across the basic science laboratory into animal models of resuscitation and to human therapies. He has been a leader in the field of resuscitation for more than 25 years, pioneering advances in improving the quality of CPR, AED use, defining the “three-phase” model for cardiac arrest care and therapeutic hypothermia. He has worked closely with the American Heart Association in emphasizing the importance of a “systems of care” approach to improving survival within communities.
Dr. Becker’s cellular studies have helped define reperfusion injury mechanisms, mitochondrial oxidant generation, reactive oxygen and nitrogen species responses to ischemia, apoptotic activation following ischemia, signaling pathways, new cellular cytoprotective strategies and hypothermia protection. He has received numerous honors and awards from organizations such as the American Heart Association, the American College of Emergency Physicians and American Society of Critical Care.
A recipient of prestigious teaching awards, Dr. Becker has mentored many successful researchers. He is a renowned, well-funded researcher who holds many patents for his discoveries. His professional affiliations include membership in the American Heart Association, Society of Academic Emergency Medicine, the US Institute of Medicine, the National Academy of Science, the American College of Emergency Physicians and the American Physiological Society. In addition, he holds many offices in professional and scientific societies, and has organized many national and international scientific meetings. He is an elected member of the Institute of Medicine/National Academy of Medicine.
Before joining Northwell, Dr. Becker was founder and director of the Center for Resuscitation Science at the Hospital of the University of Pennsylvania in Philadelphia, and professor of the Center for Mitochondrial and Epigenomic Medicine at the Children’s Hospital of Philadelphia. He was previously founder and director of the Emergency Resuscitation Center at the University of Chicago and Argonne National Laboratory.
Dr. Becker received his medical degree from the University of Illinois, College of Medicine.
Lidia Fonseca is Executive Vice President, Chief Digital and Technology Officer, responsible for developing and implementing an enterprise-wide digital strategy and roadmap. Lidia leads all digital, data and technology solutions across the company.
In her prior role, she was the Senior Vice President and CIO at Quest Diagnostics (NYSE:DGX), where she led technology, informatics and digital solutions. Lidia led the effort to create Quest’s innovative Quanum™ brand of healthcare IT and data analytics technologies, as well as leading-edge consumer technologies and digital solutions, including the MyQuest app with 6.5 million subscribers. This suite of solutions was designed to address gaps in care, improve quality, optimize utilization, and support the industry’s evolution to value-based healthcare. Additionally, she was responsible for Quest’s bioinformatics, focused on the use of data for advanced diagnostic services, as well as efforts to digitally enable and standardize operations to better serve its customers.
Lidia received the 2017 Forbes CIO Innovation Award, and she is a founding member of Synaptic Health Alliance, leading healthcare companies using Blockchain technology to improve provider data quality.
Lidia is a member of the Board of Directors of Tegna, Inc. (NYSE: TGNA). She earned a BA from University of California, Berkeley and an MBA and Master Business Informatics from Rotterdam School of Management, Erasmus Graduate School of Business.
One of TV’s most respected medical journalists, Dr. Max Gomez has produced award-winning health and science segments for network stations in New York and Philadelphia. Dr. Max has reported for Dateline, The Today Show and 48 Hours. He is currently the senior medical correspondent for WCBS, the flagship CBS network station in New York.
Over more than three decades, he’s earned nine Emmy Awards, three NY State Broadcaster’s Association awards and UPI’s “Best Documentary” award.
In addition to NYC’s ‘Excellence in Time of Crisis’ for his September 11 coverage, Dr. Max has been singled out nationally for special award recognition by the Leukemia and Lymphoma Society and The National Marfan Foundation. He was also named the American Health Foundation’s “Man of the Year”.
Dr. Gomez has served on the national board of directors for the American Heart Association, the Princeton Alumni Weekly, and Partnership for After School Education. He has chaired the national communications committees for the American Heart Association and the American Association for the Advancement of Science.
Dr. Max helped organize and moderate four international scientific conferences on stem cells and cell-based medicine co-sponsored by and held at the Vatican.
A noted moderator, speaker and media trainer, Dr. Max also mentors undergraduate journalism students as well as medical students and physicians who are interested in medical journalism.
Dr. Max is the co-author of “Cells are the New Cure – The Cutting Edge Medical Breakthroughs that are Transforming Our Health” as well as “Our Stem Cells – The Mysteries of Life and Secrets of Healing”, and “The Prostate Health Program: A Guide to Preventing and Controlling Prostate Cancer.”
Dr. Max is an honors graduate of Princeton University, received his PhD in Neuroscience from the Wake Forest University School of Medicine and was an NIH postdoctoral fellow at Rockefeller University.
Michael J. Dowling is president and chief executive officer of Northwell Health, which delivers world-class clinical care throughout the New York metropolitan area, pioneering research at the Feinstein Institute for Medical Research and a visionary approach to medical education highlighted by the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the School of Graduate Nursing and Physician Assistant Studies.
Northwell Health is the largest integrated health care system in New York State with a total workforce of more than 66,000 employees — the state’s largest private employer. With 23 hospitals, 6,675 hospital and long-term care beds, more than 665 outpatient physician practices and a full complement of long-term care services, Northwell is one of the nation’s largest health systems, with $11 billion in annual revenue.
Prior to becoming president and CEO in 2002, Mr. Dowling was the health system’s executive vice president and chief operating officer. Before joining Northwell Health in 1995, he was a senior vice president at Empire Blue Cross/Blue Shield. Mr. Dowling served in New York State government for 12 years, including seven years as state director of Health, Education and Human Services and deputy secretary to the governor. He was also commissioner of the New York State Department of Social Services.
Before his public service career, Mr. Dowling was a professor of social policy and assistant dean at the Fordham University Graduate School of Social Services, and director of the Fordham campus in Westchester County.
Mr. Dowling has been honored with many awards over the years. They include: his selection as the Grand Marshal of the 2017 St. Patrick’s Day Parade in New York City; induction into the Irish America Hall of Fame; the 2012 B’nai B’rith National Healthcare Award, the Ellis Island Medal of Honor, the 2011 Gail L. Warden Leadership Excellence Award from the National Center for Healthcare Leadership, the 2011 CEO Information Technology Award from Modern Healthcare magazine and the Healthcare Information and Management Systems Society, the National Human Relations Award from the American Jewish Committee, the Distinguished Public Service Award from the State University of New York’s Nelson A. Rockefeller College of Public Affairs and Policy, an Outstanding Public Service Award from the Mental Health Association of New York State, an Outstanding Public Service Award from the Mental Health Association of Nassau County, the Alfred E. Smith Award from the American Society for Public Administration, and the Gold Medal from the American Irish Historical Society. For 11 consecutive years, Modern Healthcare has ranked Mr. Dowling on its annual list of the “100 Most Powerful People in Healthcare.” In March 2016, Mr. Dowling was also listed No. 1 on Long Island Press’ 2015 “Power List” recognizing the 50 most-influential Long Islanders.
Mr. Dowling is chair of the Healthcare Institute and the Institute for Healthcare Improvement (IHI). He is a member of the Institute of Medicine of the National Academies of Sciences and the North American Board of the Smurfit School of Business at University College, Dublin, Ireland. He also serves as a board member of the Long Island Association. He is past chair and a current board member of the National Center for Healthcare Leadership (NCHL), the Greater New York Hospital Association (GNYHA), the Healthcare Association of New York State (HANYS) and the League of Voluntary Hospitals of New York. Mr. Dowling was an instructor at the Center for Continuing Professional Education at the Harvard School of Public Health.
Mr. Dowling grew up in Limerick, Ireland. He earned his undergraduate degree from University College Cork (UCC), Ireland, and his master’s degree from Fordham University. He also has honorary doctorates from Queen’s University Belfast, University College Dublin, Hofstra University, Dowling College and Fordham University
Paurvi Bhatt is the Vice President of Medtronic Philanthropy and President of Medtronic Foundation, leading the philanthropic and community affairs strategies of Medtronic, PLC.
Medtronic is the global leader in medical technology, focused on innovative solutions to fulfill its global Mission: to alleviate pain, restore health and extend life. The company’s philanthropic efforts are centered on leveraging its people, products and programs to expand access to chronic disease care to underserved communities worldwide.
Paurvi is a seasoned global health and development leader, with a distinguished career delivering innovative and successful cross-disciplinary solutions to challenging issues of scale and sustainability. Her focus includes strategic philanthropy and investment; corporate social responsibility; health benefit reimbursement, and partnership design particularly in emerging markets and resource poor settings. She has shaped best practice health and social responsibility portfolios in several companies including Levi Strauss and Co. and Abbott, as well as, with the government and nonprofit sector, at USAID, US GAO, and CARE. Her technical training is in health systems and economics – with specific focus on HIV/AIDS, women’s health and impact measurement.
She is known for her commitment to building the next generation of women leaders in global health, and for advocating for “working daughters”. She serves on several advisory groups and Boards focusing on leadership and global health including Last Mile Health, GlobeMed, IMPACT2030, The Conference Board – CSR Advisory Group, Women Leaders in Global Health, Global Health Council (GHC) Board, and the University of Minnesota School of Public Health Campaign Cabinet. Paurvi holds a Master of Public Health in health systems and economics from Yale University and Bachelor Degree in neuroscience from Northwestern University, is PhD (ABD) from Johns Hopkins University.
With over three decades of experience working in the nonprofit sector, Peter Wilderotter has leveraged his expertise to expand and advance the mission of several organizations.
Peter was appointed as the President and Chief Executive Officer of the Christopher & Dana Reeve Foundation in 2007 after revamping how the organization approached fundraising. Reporting to the Board of Directors, Peter is responsible for setting the overarching vision for the Reeve Foundation and rallying support for initiatives that speed the delivery of treatments for spinal cord injury.
Before locking arms with the Reeve Foundation, Peter was the Vice President of Development at WNYC Radio, America’s largest public radio station. Previously, Peter held leadership roles at Planned Parenthood Federation of America and the NAACP, and started his career at the American Cancer Society.
Ramon Soto is a skilled marketing executive with deep healthcare and financial services experience. He has a demonstrated ability to create vision, establish long-term strategies and lead cross-functional teams. Ramon has a proven track record of profitable growth in consumer and business-to-business markets. He is a passionate thought leader with strong analytic and growth skills.
Ramon is the senior vice president, chief marketing and communications officer for Northwell Health, where he is responsible for the development and execution of Northwell’s brand strategy, as well as for all aspects of marketing and communications including public relations, digital engagement, strategic marketing, clinical marketing and customer acquisition.
Ramon is a member of Northwell Health’s executive council, responsible for shaping the growth strategy and execution for the enterprise. Northwell Health is New York’s largest healthcare provider with a network of 23 hospitals, 750 community, research and clinical facilities. Northwell is NY State’s largest private employer with over 69,000 employees. With 5 million patient visits in 2018, Northwell Health is also one of the fastest growing healthcare providers in the country. Its market reach has expanded through acquisition of new hospital facilities and organic growth of ambulatory facilities, physician practices and joint ventures.
Ramon was formerly the chief marketing officer for Magellan Health, a healthcare services company focused on the unmet needs of individuals in the fast growing, highly complex and high cost areas of healthcare.
Prior to Magellan, Ramon was a senior vice president with Aetna, managing the global marketing function for the Aetna’s commercial businesses. Ramon ran the marketing function for Aetna’s national accounts, middle market, small group, specialty product and international business divisions, representing $32 billion in annual revenue.
Before his time at Aetna, Ramon spent several years at GE Capital leading the marketing function for several of GE’s consumer and commercial facing businesses.
Ramon is a graduate of the Yale School of Management’s MBA program for executives with a concentration in Healthcare. He serves on the Yale School of Management Alumni Board of Directors. He is also a graduate of GE Capital’s Leadership Interchange, a high potential manager training program. He is Six Sigma certified, was awarded a U.S. government patent for co-development of GE Capital’s product development process and was an instructor at GE’s Small Business College.
Ramon received his B.A. from the State University of New York at Binghamton in 1988.
Richard Barakat is an internationally recognized surgeon and clinical investigator who was Chief of the Gynecology Service at Memorial Sloan Kettering from 2001 to 2013 and held the Ronald O. Perelman Chair in Gynecologic Surgery. Dr. Barakat was the lead investigator on several influential research projects at MSK, including a study to compare the benefits of laparoscopic versus standard surgery for patients with endometrial cancer, a study evaluating symptomatic lower-extremity lymphedema in women treated for uterine corpus cancer, and a study testing the efficacy of the Gynecologic Cancer Lymphedema Questionnaire in detecting lower-extremity lymphedema symptoms. Dr. Barakat is author or co-author of more than 340 peer-reviewed articles and numerous textbook chapters and is also an editor of a surgical atlas on gynecologic cancer and of the latest edition of Principles and Practice of Gynecologic Oncology, one of the leading texts in the field.
In addition he served as a member and examiner for the American Board of Obstetrics and Gynecology and for five years served as Vice Chairman of the Cancer Prevention Committee of the Gynecologic Oncology Group. He was President of the Society of Gynecologic Oncology from 2013 to 2014 and past President of the International Gynecologic Cancer Society (2014-2016). From 2013 -2017, he served as Director of the MSK regional network.
In 2018 Dr. Barakat joined Northwell Health to lead all cancer services and research and serve as professor of Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Sendhil Mullainathan is the Roman Family University Professor of Computation and Behavioral Science at Chicago Booth. His current research uses machine learning to understand complex problems in human behavior, social policy, and especially medicine, where computational techniques have the potential to uncover biomedical insights from large-scale health data. He currently teaches a course on Artificial Intelligence.
In past work he has combined insights from economics and behavioral science with causal inference tools—lab, field, and natural experiments—to study social problems such as discrimination and poverty. Papers include: the impact of poverty on mental bandwidth; how algorithms can improve on judicial decision-making; whether CEO pay is excessive; using fictitious resumes to measure discrimination; showing that higher cigarette taxes makes smokers happier; and modeling how competition affects media bias.
Mullainathan enjoys writing. He recently co-authored Scarcity: Why Having too Little Means so Much and writes regularly for the New York Times. Additionally, his research has appeared in a variety of publications including the Quarterly Journal of Economics, Science, American Economic Review, Psychological Science, the British Medical Journal, and Management Science.
Mullainathan helped co-found a non-profit to apply behavioral science (ideas42), co-founded a center to promote the use of randomized control trials in development (the Abdul Latif Jameel Poverty Action Lab), serves on the board of the MacArthur Foundation, has worked in government in various roles, is affiliated with the NBER and BREAD, and is a member of the American Academy of Arts and Sciences.
Prior to joining Booth, Mullainathan was the Robert C. Waggoner Professor of Economics in the Faculty of Arts and Sciences at Harvard University, where he taught courses about machine learning and big data. He began his academic career at the Massachusetts Institute of Technology.
Mullainathan is a recipient of the MacArthur “Genius Grant,” has been designated a “Young Global Leader” by the World Economic Forum, was labeled a “Top 100 Thinker” by Foreign Policy Magazine, and was named to the “Smart List: 50 people who will change the world” by Wired Magazine (UK). His hobbies include basketball, board games, googling, and fixing up classic espresso machines.
Susan L. Solomon is the Chief Executive Officer and Founder of the New York Stem Cell Foundation Research Institute (NYSCF). Ms. Solomon is a veteran healthcare advocate and stem cell research pioneer who serves on the boards of a number of prominent diabetes and regenerative medicine organizations, including the College Diabetes Network, the Global Alliance for IPSC Therapies, and the strategic planning committee for the inaugural NYSTEM program. She also serves on the Board of Directors of the Regional Plan Association, where she is a member of the nominating and governance committee.
A lawyer by training and a chief executive and entrepreneur by experience, Ms. Solomon has decades of leadership experience in starting and building effective and focused organizations. Ms. Solomon started her career as an attorney at Debevoise and Plimpton, then held executive positions at MacAndrews and Forbes and APAX (formerly MMG Patricof and Co.). She was the founder and President of Sony Worldwide Networks, the Chairman and Chief Executive Officer of Lancit Media Productions, an Emmy award-winning television production company, and then served as the founding Chief Executive Officer of Sothebys.com, prior to starting her own strategic management consulting firm Solomon Partners LLC in 2000. She received her BA cum laude from New York University and her JD from Rutgers University School of Law, where she was as an editor of the Law Review.
Ms. Solomon has received numerous awards for her work with NYSCF, including the New York State Women of Excellence Award from the Governor of New York, the Triumph Award from the Brooke Ellison Foundation, and recognition as a Living Landmark from the New York Landmarks Conservancy.
Dr. Thomas Lee is an internist and cardiologist who practices at Brigham and Women’s Hospital in Boston, Massachusetts. He is a Professor of Medicine, part time, at Harvard Medical School and Professor of Health Policy and Management at the Harvard School of Public Health. He currently serves as Chief Medical Officer to Press Ganey, Inc. Prior to joining Press Ganey in 2013, Dr. Lee was the Network President for Partners Healthcare System, the integrated delivery system founded by Brigham and Women’s and Massachusetts General Hospitals in 1994.
Dr. Lee has performed clinical epidemiological research leading to more than 300 articles in peer-reviewed journals, and three books. He is a member of the Editorial Board of The New England Journal of Medicine, the Board of Directors of Geisinger Health System, the Board of Directors of Health Leads; the Board of Overseers of Weill Cornell Medical College; the Special Medical Advisory Group (SMAG) of the Veterans Administration; and the Panel of Health Advisors of the Congressional Budget Office.
He received is BA from Harvard College (1975) and his MD from Cornell University Medical College (1979), and then trained in internal medicine and then cardiology at Brigham and Women’s Hospital. He received a MSc in Epidemiology from Harvard School of Public Health in 1987.
As the past Director of the Human Genome Project for US. Department of Energy, Dr. Hawkins has built a recognized career in the healthcare industry over the past 25 years spanning business, academic innovation and as an entrepreneur.
Dr. Hawkins is currently the Founder & Managing Partner at IGenes LLC, a consulting and investment firm working with a portfolio of global companies. Clients include General Electric, Northwell Health, Ping An, Google, Grifols, Ativa Medical, Data Cubed and BioElectron Pharmaceuticals. Dr. Hawkins is also a visiting professor at NYU.
IGenes LLC provides consulting services to companies ranging from technology roadmaps, strategy development and evaluation, market modeling, product development roadmaps and regulatory approval. On the investment services front, IGenes has completed financing in excess of $250M drawing on a wide network of early-mid stage investors.
Previously, Dr. Hawkins has held several senior executive roles at Siemens Healthcare, Philips and General Electric. He was also a successful entrepreneur building and selling a diagnostic company based in Shanghai & San Francisco.
Dr. Hawkins has published over 50 peer-reviewed articles on automation, genomics, human diseases and the human genome project in addition to writing a book, “Solving the Healthcare Equation” which is expected to be completed in 2020.
Tyler Mathisen co-anchors CNBC’s “Power Lunch,” one of the network’s longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network’s events team to grow the rapidly expanding business.
Previously, Mathisen was co-anchor of “Nightly Business Report,” an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network’s daily content and coverage. He was also co-anchor of CNBC’s “Closing Bell.”
Mathisen has reported one-hour documentaries for the network including “Best Buy: The Big Box Fights Back,” “Supermarkets Inc: Inside a $500 Billion Money Machine” and “Death: It’s a Living.” Mathisen was also host of the CNBC series “How I Made My Millions.”
Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine’s mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.
In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on “Caring for Aging Parents,” which aired on ABC’s “Good Morning America.” Mathisen served as money editor of “GMA” from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York’s WCBS-TV.
A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.
Vik is a Managing Director at Foresite, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare.
Prior to joining Foresite Capital, Vik was the Chief Scientific Officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the Co-Founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and served as Chair of its Scientific Advisory Board. A former academic principal investigator, Vik retains appointments as Associate Professor (consulting) at the Stanford School of Medicine, and as an Affiliate Scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology.
Vik’s research interests lie at the interface of the physical sciences, engineering, and the life sciences. He and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point-of-care testing, methods and devices that dramatically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics and integrative systems biology. Aspects of this work have been commercialized through several startups. At GRAIL, Vik led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development.
He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy’s LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences.
Wolfgang Baiker, M.D., Ph.D., M.B.A., is the President and Chief Executive Officer (CEO) of BI USA and the US Country Managing Director. Dr. Baiker leads the team that ensures the company’s success in the US for all of BI’s businesses, including Human Pharma, Animal Health and Bio Manufacturing.
Prior to this position, Dr. Baiker served as Senior Vice President, Human Pharma Supply & Global Quality, as well as Head of the Biopharma Business Unit. He joined Boehringer Ingelheim in 1989 as Section Head for Clinical Development in Biberach, Germany.
Since then, Dr. Baiker has held a number of senior leadership roles across several critical business functions, including Head of International Project Management; Head of Global Development; Member of the Board of Managing Directors (BMD) responsible for Corporate Board Division Biopharmaceuticals and Operations; and currently, as a key member of the Human Pharma Executive Committee.
Dr. Baiker completed his medical studies and doctorate at the Universities of Bochum, Berlin, Ulm, Munich and Sheffield and received his MBA from Pace University in New York.